Multiparametric Highly Sensitive Chemiluminescence Immunoassayfor Quantification of b-Lactam-Specific Immunoglobulin E by Quintero-Campos, Pedro et al.
 
Document downloaded from: 
 

























Quintero-Campos, P.; Juárez-Rodríguez, MJ.; Morais, S.; Maquieira Catala, Á. (2020).
Multiparametric Highly Sensitive Chemiluminescence Immunoassayfor Quantification of b-




This document is the Accepted Manuscript version of a Published Work that appeared in
final form in Analytical Chemistry, copyright © American Chemical Society after peer review
and technical editing by the publisher. To access the final edited and published work see
https://doi.org/10.1021/acs.analchem.0c03020
 
A multiparametric highly sensitive chemiluminescence immunoassay 
for quantification of β-lactam-specific Immunoglobulin E 
Pedro Quintero-Campos1, María José Juárez1, Sergi Morais*1,2,3, Ángel Maquieira1,2,3 
1Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat 
Politècnica de València-Universitat de València, Camino de Vera s/n, (46022) Valencia, Spain. 
2Departamento de Química, Universitat Politècnica de València, Camino de Vera s/n, (46022) Valencia, Spain.  
3Unidad Mixta UPV-La Fe, Nanomedicine and Sensors, IIS La Fe, Av. Fernando Abril Martorell, (46026), Valencia, Spain 
Author e-mail: smorais@upv.es; 
ABSTRACT: β-lactams (BLCs) are the most widely used antibiotics, and consequently the most common cause of drug allergy in 
the world. The diagnosis of drug allergy is complex and represents a serious challenge that includes a wide variety of methods. In 
vitro tests are based on immunological determination of allergen-specific IgE, but the tests in the market lack the required sensitivity 
and specificity. Also, the large sample volume, long incubation times and single-plex configuration have brought their use into ques-
tion to complement the clinical information. Here, we report a chemiluminescence immunoassay (CLIA) for multiparametric quan-
tification of specific IgE to penicillin G, penicillin V, amoxicillin and piperacillin, using histone H1 as carrier. The developed CLIA 
allowed the determination of BLCs-specific IgE below 0.1 IU/mL, allowing identifying allergic patients with better sensitivity, using 
only 25 μL of sample (serum). The immunoassay was successfully applied in a cohort of 140 human serum samples, showing good 
sensitivity (64.6 %) as well as specificity (100 %), what significantly improve the predictive character of existing BLCs-allergy in 
vitro tests.
INTRODUCTION 
β-lactams antibiotics (BLCs) are the most widely used drug 
to fight bacterial infections worldwide due to their efficacy, 
safety and price, representing 65% of the world antibiotic mar-
ket1. Among the BLCs, penicillin, amoxicillin and amoxicillin-
clavulanate are the utmost prescribed2. However, it is estimated 
that these antibiotics are the most common cause of drug allergy 
in the world, with prevalence ranging from 5% to 10% in the 
general population3 and have an approximate frequency of 81% 
of all allergic drug reactions in children4. The overall consump-
tion of antibiotics ranged from 4.4 to 64.4 Defined Daily Doses 
(DDD) per 1000 inhabitants per day2, what might make allergy 
episodes to occur. 
One of the four types of allergy is associated to IgE-mediated 
type I hypersensitivity reactions and its diagnosis is complex 
and represents a serious challenge that includes a wide variety 
of methods5. In vivo methods (skin test or drug provocation test) 
are invasive and risky of a new allergic reaction, even causing 
anaphylaxis in the most severe causes6. On the other hand, in 
vitro methods are based on the detection of specific IgE and are 
useful in the identification of the causative culprit drug without 
any risk6. In fact, it is the only method able to determine directly 
the levels of drug-specific IgE (sensitization). A positive spe-
cific IgE response accompanied with a history of allergic symp-
toms make the diagnosis of drug allergy clinically relevant7. 
In recent years, a variety of in vitro tests have been developed 
that can determine the level of specific IgE in blood or serum 
for food and environmental allergens. The vast majority of these 
methods are multiplex and they are based on the simultaneous 
determination of specific IgE against different allergens. Some 
of them are AdvanSure AlloScreen Max (LG Chem), Polycheck 
Allergy (Biocheck), ALEX Allergy Explorer (Macro Array Di-
agnostics) and IVD Capsule Aeroallergens (Abionic SA). These 
methods require specific and expensive equipment, their test 
times can reach more than three hours and they use large vol-
umes of sample. Despite differences in the methodology, these 
methods have very similar characteristics, with detection limits 
in the 0.35 IU/mL level and high clinical sensitivity8–10. How-
ever, in vitro tests for drug allergy diagnosis to β-lactams are 
scarcely developed. 
In clinical practice, a low variety of in vitro serological tests 
have been developed to detect specific IgE to β-lactam antibi-
otics in serum, including RAST (Radio Allegro Sorbent Test), 
fluorescence enzyme assays (as ImmunoCAP) and ELISA (En-
zyme linked immunosorbent assay)11. 
RAST method is outdated due to the inconvenience of using 
radioactive isotopes, inefficiency and high cost12. This assay has 
been replaced by fluoroenzyme assays as ImmunoCAP 
(Thermo Fischer Scientific), which is perceived as the reference 
method for the in vitro detection of specific IgEs. However, Im-
munoCAP does not cover all allergens and the cut-off value 
considered positive is 0.35 kUA/L. Despite their differences, 
IMMULITE (Siemens) is another method to detect specific IgE. 
Both methods have many weaknesses such as test time, sample 
volume, the semiquantitative character, the cost per assay-aller-
gen13 and are far from representing an effective and reliable al-
ternative to in vivo tests, showing a poor sensitivity of 25%3,14.  
This makes that even though approximately 15% of the world 
population are labelled as allergic to BLCs15, most diagnoses of 
β-lactams allergy are related to events that are not allergic in 
nature, and therefore, are associated with negative clinical and 
 
administrative outcomes, including use of less desirable alter-
native antibiotics, longer hospitalizations, increasing antibiotic-
resistant infections, and greater medical costs16. BLCs allergy 
de-labelling has become a global operationalizing focused to 
avoid unnecessary treatment and inferior results with alterna-
tive agents as well as adverse public health outcomes such as 
antibiotic resistance17. 
Consequently, there is a clinical-commercial demand for new 
diagnostic methods that meet the requirements of sensitivity, 
specificity, speed, simplicity, for their implementation in all 
types of clinical laboratory settings of different levels of health 
care. 
ELISA has been widely used as a sensitive and selective 
method in analytical assays, so it can represent a valid alterna-
tive to FEIAs, being relatively simple and inexpensive for the 
assessment of serum sIgE for common allergens7. However, 
this method often requires large volumes of sample and con-
sumes long incubation time in the whole process. Nevertheless, 
assay optimization processes could lead to very sensitive and 
selective ELISAs using less sample volume and taking less test 
time. At last, one alternative to improve immunoassay sensitiv-
ity is to incorporate chemiluminescence into the standard 
ELISA protocols (CLIA). This technique has the potential to 
improve sensitivity by at least 2-3 orders of magnitude com-
pared to conventional colorimetric detection18. In this type of 
assays, luminol is used as substrate for the HRP-labelled anti-
body19. 
In addition, this technology allows estimating the sensitiza-
tion profile of each patient, enabling individualized and preci-
sion therapy, in line with the emerging strategy aimed at focus-
ing on the individual characteristics of each patient for preven-
tion, diagnosis and treatment of the illness. 
To the best of our knowledge, we here report the first mul-
tiparametric CLIA-based method for the in vitro determination 
of specific IgE for amoxicillin, penicillin G, penicillin V and 
piperacillin IgE-mediated drug allergic reactions for commonly 
prescribed and consumed β-lactam antibiotics.  
 
MATERIALS AND METHODS 
Reagents, buffers, consumables and instruments 
Histone H1, penicillin G, penicillin V, amoxicillin and pipe-
racillin were from Sigma-Aldrich (Madrid, Spain). Omali-
zumab was from Novartis International AG (Basel, Switzer-
land). WHO reference IgE standard 11/234 was from the Na-
tional Institute for Biological Standards and Control (Hertford-
shire, United Kingdom). Mouse monoclonal antibody anti-hu-
man IgE (-IgE) was from Eurofins Ingenasa S.A. (Madrid, 
Spain). Goat anti-mouse IgG preabsorbed (GAM-HRP) was 
purchased from Abcam (Cambridge, United Kingdom). En-
hanced chemiluminescent substrate solution was acquired from 
Thermo Fisher (Madrid, Spain). Coating buffer was 50 mM so-
dium carbonate/bicarbonate, pH 9.6, and washing buffer 10 
mM sodium phosphate buffer, 150 mM NaCl, 0.05% Tween 
20%, pH 7.4 (PBS-T). 
High binding white polystyrene ELISA plates were from 
Costar Corporation (Cambridge, MA, USA), the ELISA plate 
washer from Nunc Maxisorp (Roskilde, Denmark) and the En-
Spire Multimode Plate Reader from PerkinElmer (Waltham, 
MA, USA). 
 
Preparation of coating antigens 
β-lactam-lloyl antigens were prepared following the method 
described by Edwards with slight modifications20. Briefly, β-
lactam antibiotics (penicillin G, penicillin V, piperacillin and 
amoxicillin at 50 µmol) reacted with the carrier protein (H1 at 
0.25 µmol) in 1.5 mL of 0.1 M sodium carbonate, pH 11.0 over-
night at room temperature. The antigens were purified by cen-
trifugal filters (Amicon Ultra centrifugal filters) using PBS (10 
mM sodium phosphate buffer, 150 mM NaCl, pH 7.2) as buffer 
exchange. The antigens were stored at -20 ºC till use.  
Assay procedure for multiparametric chemiluminescence im-
munoassay 
A scheme of the chemiluminescence immunoassay procedure 
is depicted in Figure 1. First, white flat-bottomed polystyrene 
ELISA plates were coated with antigen solutions (3.0 mg/L) in 
coating buffer (25 μL/well) for the direct determination of spe-
cific IgE to β-lactam antibiotics. Also, 25 μL of omalizumab 
solution (0.5 mg/L in coating buffer) was used to coat wells as 
the capture antibody for the determination of total IgE concen-
tration in a sandwich format for calibration purposes. The plates 
were then sealed and incubated overnight at 4 °C. The following 
day, plates were washed four times with PBS-T and after that 
25 μL/well of sera and WHO standards were added to each well, 
followed by incubation for 30 min at room temperature. Serum 
samples were analyzed in triplicate and sIgE-free serum 
(H4522, Sigma-Aldrich) was used as negative control. One cal-
ibration curve (WHO standards in triplicate) was made on each 
ELISA plate. Then, the wells were washed as before. Next, 25 
µL of monoclonal antibody anti-human IgE solution (1/2000 
dilution) was added to each well. After 15 min, the plate was 
washed as before and 25 µL of goat anti-mouse IgG preab-
sorbed solution (1/500) were added to each well and incubated 
again for 15 minutes. After washing the wells as before, the pe-
roxidase activity was measured by adding 25 µL of enhanced 
chemiluminescent substrate solution previously diluted 1/10 in 
PBS. The luminescent signals were read at 450 nm, using the 
Multimode Plate Reader.  
 
Figure 1. Scheme of the multiparametric chemiluminescence 
immunoassay in a 96-well microplate for the determination of 
specific and total immunoglobulin E (IgE) to β-lactam antibiot-
ics in human serum. 
Allergen-specific IgE levels expressed as IU/mL were deter-
mined, using the WHO standards, involving heterologous inter-
polation as a calibration method. The limit of detection (LOD) 
and quantification (LOQ) was calculated measuring the signal 
of the blank ten times and interpolating the mean of the signal 
plus 3 and 10 times the standard deviation to the calibration 
curve, respectively. Likewise, a representative serum sample 
with known specific IgE concentration, measured by the refer-
ence in vitro ImmunoCAP method, was used as calibrator to 




Serum samples from 140 adults were collected in red-top 
tubes (BD Diagnostics, Madrid, Spain), incubated at room tem-
perature for 60 minutes to induce clotting. After centrifugation 
at 2000 rpm for 15 minutes, the serum was aliquoted into cryo-
vials and stored at -80ºC till use. A cohort of 71 allergic patients 
(allergic to at least one of the four β-lactam antibiotics under 
study) and 69 non-allergic to BLCs individuals (controls) were 
included in the study. The clinical history of the patients in-
cluded the result of the prick test to different ß-lactam antibiot-
ics and the concentration of specific IgE measured by the Im-
munoCAP test. All participants were enrolled after giving writ-
ten informed consent according to protocols approved by the 
ethics review board at La Fe University Hospital (registry no. 
COBIOPHAD). The procedures followed were in accordance 
with the Helsinki Declaration of 1975 as revised in 2008. The 
patients were diagnosed following the procedure described in 
the European Network of Drug Allergy (ENDA) protocol based 
on skin testing, in vitro tests or drug provocation test, whenever 
necessary.  
Statistical analysis 
Coefficients of variation and parameters of assay sensitivity 
were determined by standard descriptive statistical methods us-
ing Microsoft Excel 365 (Microsoft Corporation). The standard 
data points were plotted and a four-parameter logistic (4PL) 
curve was fitted through the points, using SigmaPlot 12 (Systat 
Software Inc). ANOVA statistical analysis, multiple regression 
analysis and the correlation study were carried out using SPSS 
Statistics (IBM). Clinical sensitivity and specificity were calcu-
lated using MedCalc (MedCalc Software) using ImmunoCAP 
as reference method. 
 
RESULTS AND DISCUSSION 
Assay optimization 
The time and reagent volume required to perform an ELISA 
test are the main reasons why this type of assays is not com-
monly used for allergy diagnosis. To overcome these two dis-
advantages, an assay optimization study was carried out. His-
tone H1-Amoxicillin conjugate (H1-AMX) was chosen as anti-
gen and a well-characterized serum sample, with known con-
centration of specific IgE to amoxicillin (3.3 IU/mL, according 
to the ImmunoCAP results) was used. This study was carried 
out, using 3-fold serial dilutions (1/3-1/27) made up with con-
trol serum samples from non-allergic patients. 
First, the blocking step was excluded. The assay was com-
pared with and without a blocking step, and statistical analysis 
of the data through a multiple regression analysis using SPSS 
Statistics (IBM) showed that there were no statistically signifi-
cant differences between both methodologies (p=0.265) (Figure 
S1). This might be probably due to the blocking effect of serum 
proteins. 
Secondly, a decrease in incubation time and sample volume 
required to perform the test was carried out. The goal was to 
move from a 3 hour-assay, the time usually taken to perform a 
regular ELISA, to 65 min-assay; 30 min for serum sample in-
cubation step, and 15 min for both the primary and secondary 
antibody incubation.  
The volume of both the reagents and sample as well as the 
total assay time were evaluated by carrying out four assays: 100 
µL of sample and each reagent, and a total assay time of 3 hours 
(standard protocol); and 50, 25 and 10 µL of sample and each 
reagent with a one-hour total assay time. Once the test was per-
formed, as can be seen in Figure 2, a proportional reduction in 
the luminescent signal was observed when the test volumes and 
time decreased.  
 
Figure 2. Results of the optimization assays (A-D) with His-
tone-AMX as antigen and a representative positive serum sam-
ple. A: Standard protocol (100 µL of volume used and total as-
say time 3 h). B, C and D: 50, 25 and 10 µL of volume used, 
respectively, and total assay time was approximately 1 h. The 
group of bars (A-D) correspond to specific IgE concentration to 
amoxicilin [IgE]. From the left to the right the concentration 
was 3.3; 1.1; 0.35; 0.12 and 0 IU/mL.  
By analyzing each of the experiments separately, the data sta-
tistics show that when 10 µL of sample is used there is no sta-
tistically significant difference between the average light signal 
and the different IgE concentrations. When the volume used to 
perform the ELISA is 100, 50 and 25 µL the ANOVA statistical 
analysis establishes the existence of statistically significant dif-
ferences in the light signal as the specific IgE concentration var-
ies.  
To compare the use of different volumes, a multiple regres-
sion analysis was performed. It established that the only varia-
ble that produced statistically significant changes in the light 
signal (dependent variable) was the specific IgE concentration 
(p < 0.05), and that both the volume (p=0.210) and the time of 
test performance (p = 0.810) did not significantly influence the 
final result. 
So, taking into account all the results, the test was switched 
to use a volume of 25 µL and 1h total assay time. Compared to 
other immunoassays with the same number of steps, high sen-
sitivity was achieved with reduced incubation time. In addition, 
the volume of 100 µL typically used in a standard ELISA pro-
tocol has been reduced from the 50 µL of serum required to 
perform IgE analysis with IMMULITE (Siemens)21 or the 40 
µL used in the most up-to-date ImmunoCAP (Phadia) equip-
ment22. 
Evaluation of antigens performances 
Antigens are the essential element to develop a sensitive and 
selective assay for the determination of specific IgE antibodies 
to antibiotics. This is because BLCs are low-molecular-weight 
molecules incapable of inducing an immune response on their 
own. Protein haptenization is the process that occurs through 
the nucleophilic opening of the β-lactam ring and results in pro-
tein-antibiotic antigens capable of triggering the immune re-
sponse6. For this reason, the carrier molecule is key to induce 
 
sensitization and consequently it is responsible to activate the 
immune system in order to produce specific IgE antibodies 
against a particular epitope. In this study, histone H1was used 
as carrier molecule to conjugate the β-lactam antibiotics. His-
tone H1 is a lysine rich protein that contains tens of primary 
amines available for coupling β-lactam antibiotics, enabling 
high-yield conjugations.  
Linearity-of-dilution tests were carried out for validating and 
assessing the accuracy of CLIA, using the H1-AMX antigen. 
These tests were performed with a reference serum with known 
concentration of specific IgE for amoxicillin (7.0 IU/mL as 
measured by ImmunoCAP), using 3-fold serial dilutions (1/3-
1/81). Dilutions were made with a pooled (n = 69) control serum 
sample as diluent. As is shown in Figure 3, the linearity was 
good over a wide range of dilution, revealing that the method-
ology provided flexibility to test human serum samples with 
different levels of specific IgE. The lowest specific IgE concen-
tration to amoxicillin likely to be reliably distinguished from the 
diluent (negative control) was 0.03 IU/mL. 
 
Figure 3. Dilution linearity study (r2 = 1) of the assay using 
a serum sample as matrix to evaluate the accuracy of the CLIA. 
The rest of the histone derived antigens (penicillin G, peni-
cillin V and piperacillin) performed well, showing a LOD of 
0.03 IU/mL for penicillin G, V, calculated from the results ob-
tained with the linearity-of-dilution experiments (Figure S3). 
Calibration method 
A reliable quantitative method must report the results in units 
traceable to an international standard. Nowadays, it is not pos-
sible to use individual specific IgE for β-lactam antibiotics to 
perform homologous calibration method. Therefore, the cali-
bration method mostly accepted is a heterologous interpolation 
of specific immunoglobulins E from a single total immuno-
globulin reference curve. As it can be observed in Figure 4 
(solid line), the signal (n=10) fit well to a four-parameter lo-
gistic curve, achieving a limit of detection of 0.05 IU/mL and 
dynamic response ranging from 0.5 IU/mL to 8.0 IU/mL, fol-
lowing a point-to-point calculation method approach. On as-
sessment of the precision of the CLIA, CVs ranged from 1.6 to 
8.6% and resulted in a linear regression equation with correla-
tion coefficient (r) of 0.999. Likewise, a representative sample 
with known concentration of amoxicillin-specific IgE was used 
for a homologous calibration method, using the H1-AMX anti-
gen. As it can be observed in Figure 4 (dash line), the signal 
(n=6) fit well to a four-parameter logistic curve, achieving a 
limit of detection of 0.03 IU/mL. In the homologous curve, CVs 
ranged from 0.5 to 2% and resulted in a linear regression equa-
tion with correlation coefficient (r) of 1. 
 
Figure 4. Heterologous (solid line) and homologous (dashed 
line) calibration curves for specific IgE to amoxicillin by CLIA. 
Spike-and-recovery tests were carried out to evaluate the dif-
ferences in assay response, using representative serum samples. 
The results are shown in Table 1. As it can be seen, the recovery 
values ranged between 65 and 121%, revealing that the compo-
nents in the sample matrix are not causing significant differ-
ences in assay response. The relative standard deviation values 
were below 10% for all dilutions. 
Table 1. Recovery results obtained for moderate-level BLC-
specific IgE human serum samples by CLIA. 










neat 1.51 ± 0.08 
2.33 
65 
1:3 1.98 ± 0.12 85 
1:9 2.75 ± 0.15 118 
1:27 2.82 ± 0.13 121 
aDilution factor. bRecovery. Measured values were assessed 
relative to the heterologous standard curve. 
Clinical performances of the CLIA 
A cohort of 140 sera collected from allergic patients to one 
or more beta-lactam antibiotics (71) and non-allergic to beta-
lactam antibiotics (69) were analysed, using the developed 
CLIA, in triplicate for each of the selected antibiotics: penicillin 
G, penicillin V, piperacillin and amoxicillin; and quantified us-
ing the WHO heterologous calibration curve. 
For each serum, a clinical history was available with the fol-
lowing information: culprit drug of the allergic episode, result 
of skin test of penicillin G, amoxicillin and piperacillin; and the 
concentration of specific IgE against penicillin G, penicillin V 
and amoxicillin measured by ImmunoCAP.  
First, we compare the capability of each method to identify 
allergic and non-allergic individuals. Results that were above 
the detection limit (LOD) were established as positive (aller-
gic). The LOD, defined as the lowest sIgE concentration that 
can be reliably determined, was 0.05 IU/mL for amoxicillin and 
piperacillin; and 0.06 IU/mL for penicillin G and penicillin V; 
being these figures below the current internationally accepted 
cut-off concentration for allergy diagnostics (0.35 IU/ml). For 
CLIA, the cut-off was 0.04 IU/mL, providing a clinical sensi-






















































After the analysis of the controls (non-allergic patients) it is 
observed that both methods identify these samples as negative, 
since the results obtained are below LOD of each method. The 
absence of false positives ratifies the good performance of the 
CLIA method. Table 2 lists the number of patients (allergic) an-
alysed, showing the amount of positive (> LOD) and negative 
(< LOD) results obtained by both methods.  
Table 2. Number of positive and negative subjects identified 
by CLIA and ImmunoCAP (ICAP). 
Antibiotic Allergic Non-Allergic 





7 / 64 0 / 69 0 / 69 
Penicillin 
V 
15 / 56 8 / 63 0 / 69 0 / 69 
Amoxicil-
lin 
32 / 39 11 / 60 0 / 69 0 / 69 
Piperacil-
lin 
18 / 53 ND 0 / 69 0 / 69 
apositive; bnegative; ND: not determined 
As it can be inferred from the results, our CLIA system is able 
to detect greater number of sensitive people when analyzing 
samples from allergic patients, using the heterologous calibra-
tion (Table 3). Besides, the results for positive tests were com-
pared between the two methods. In spite of being analytical sys-
tems that use different antigenic determinants, the scatter dia-
gram (Figure 5A) shows good correlation (0.8670, p < 0.0001) 
between ImmunoCAP and CLIA, revealing the good precision 
of the proposed methodology. Though there are slight differ-
ences in measuring the concentration of specific IgE, CLIA per-
forms an under-quantification of IgE, using the heterologous 
calibration (WHO) curve, the difference being greater at high 
concentrations. For amoxicillin-specific IgE, quantification was 
also carried out using a homologous curve. In this case, the re-
sults are similar to those obtained using the WHO curve, under-
quantification of specific IgE was detected. At low IgE concen-
trations, the value obtained with the homology curve is very 
similar to the value obtained when quantifying with the WHO 
curve, but this behaviour changes at higher concentrations: 
lower values are obtained than with ImmunoCAP but higher 
than when using the WHO curve. This difference when using 
the curves (Figure 4) may be due to the matrix. In the case of 
the homologous curve, the matrix is raw human serum; while in 
the case of the heterologous (WHO) curve, the diluent media is 
PBS-BSA 0.1% with 0.05% Tween20. The presence of proteins 
in the serum causes a decrease in the signal with respect to less 
complex matrixes, which would explain the under-quantifica-
tion when using the WHO curve.  
In order to compare CLIA with the reference method at the 
diagnostic level, we based exclusively on the results obtained 
for amoxicillin, since most of the patients were clinically diag-
nosed as allergic to this antibiotic (47 allergic to amoxicillin).  
It is worth mentioning that all the positive results given by the 
ImmunoCAP were corroborated by the developed CLIA. The 
correlation between CLIA and ImmunoCAP was calculated us-
ing those samples that were positive by both methods. The an-
alytical sensitivity of CLIA was 0.04 IU/mL. However, Im-
munoCAP reports a diagnostic cut-off of 0.35 IU/mL for amox-
icillin and uses a Poly-L-Lysine based antigen. All these rea-
sons might be probably the cause of the poor correlation ob-
served at low concentrations. Receiver Operating Characteristic 
(ROC) (Figure 5B) analysis showed good area under the curve 
for CLIA. Indeed, both in vitro tests showed high diagnostic 
specificity since no false positives were detected. Regarding di-
agnostic sensitivity, the CLIA classified 64.6% of patients al-
lergic to amoxicillin as positive, compared with 23% identified 
by the reference test. As it can be seen, the clinical sensitivity 
of the developed assay was significantly better than that ob-
tained with ImmunoCAP as reference test. Indeed, a three-fold 
increase of sensitivity was achieved, what confirms the strength 
point of the developed CLIA method. 
 
Figure 5. (A) Scatter diagram and regression line of inter-
method comparison between CLIA and ImmunoCAP. (B) ROC 
analysis representing the area under the curve (AUC). Sensitiv-
ity and specificity of the CLIA as compared against Im-
munoCAP for amoxicillin (n = 140 values). 
Analysis of the results showed the high percentage of cross-
reactivity that exists in BLC allergy. Of the 17 patients detected 
as allergic to penicillin G, none was found to be exclusively al-
lergic to this penicillin: 88% showed cross-reactivity with 
amoxicillin, 47% with penicillin V and 71% with piperacillin. 
This is mainly because penicillin is the precursor of most β-lac-
tam antibiotics. Of the 33 patients diagnosed as allergic to 
amoxicillin only 24% were allergic to this drug alone. Of the 
remaining, 45% had cross-reactivity with penicillin G, 33% 
with penicillin V and 45% with piperacillin. In the case of those 
diagnosed by CLIA as allergic to penicillin V, 53% presented 
cross-reactivity with penicillin G, 73% with amoxicillin and 
67% with piperacillin. Only 13% of the patients diagnosed as 
allergic to penicillin V had no specific IgE capable of recogniz-
ing another of the antibiotics under study. Finally, only 6% of 
those diagnosed by CLIA as allergic to piperacillin were exclu-
sively allergic to this antibiotic. Indeed, 71% of these patients 
 
allergic to piperacillin had cross-reactivity with penicillin G, 
88% with amoxicillin and 59% with penicillin V. These antibi-
otics are characterized by having a β-lactam ring in their molec-
ular structure and are distinguished from each other by different 
side chains. Sometimes, similarity between side chains of anti-
biotics can lead to cross reactivity. In this process, a patient who 
has not been in direct contact with a certain antibiotic presents 
IgE capable of recognizing it. This information gives us a pre-
dictive diagnosis, which will avoid contacting the patient with 
an antibiotic that can trigger a high-risk allergic reaction. 
 
 
Table 3. Specific IgE concentration expressed in IU/mL to β-lactams determined by CLIA and ImmunoCAP (ICAP). 
 Penicillin G Amoxicillin Penicillin V Piperacillin 
Pa-
tient 
CLIAa ICAP CLIAa CLIAb ICAP CLIAa ICAP CLIAa 
1 <LOD 0.04 0.21 ± 0.01 0.20 ± 0.01 0.09 <LOD 0.01 <LOD 
2 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
3 0.83 ± 0.00 13.60 1.65 ± 0.01 2.87 ± 0.01 10.20 0.40 ± 0.01 13.20 2.02 ± 0.08 
4 0.22 ± 0.01 0.01 0.46 ± 0.01 0.49 ± 0.01 0.11 <LOD 0.03 0.35 ± 0.01 
5 <LOD 0.00 0.11 ± 0.01 0.09 ± 0.01 0.02 <LOD 0.02 <LOD 
6 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.00 <LOD 
7 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.01 <LOD 
8 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
9 <LOD 0.03 2.31 ± 0.01 7.02 ± 0.01 0.16 <LOD 0.00 <LOD 
10 <LOD 0.00 0.05 ± 0.00 0.05 ± 0.00 0.01 <LOD 0.00 0.12 ± 0.01 
11 0.49 ± 0.04 2.16 0.32 ± 0.03 0.33 ± 0.03 1.64 0.25 ± 0.02 1.91 0.47 ± 0.04 
12 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
13 0.05 ± 0.01 0.00 0.16 ± 0.01 0.15 ± 0.01 0.82 <LOD 0.00 0.08 ± 0.01 
14 <LOD 0.02 <LOD <LOD 0.05 <LOD 0.03 <LOD 
15 <LOD 0.03 <LOD <LOD 0.11 <LOD 0.02 <LOD 
16 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
17 <LOD 0.01 <LOD <LOD 0.04 <LOD 0.01 <LOD 
18 <LOD 0.00 0.05 ± 0.01 0.05 ± 0.01 0.01 0.08 ± 0.01 0.03 0.07 ± 0.01 
19 0.16 ± 0.01 0.00 0.12 ± 0.01 0.12 ± 0.01 0.03 <LOD 0.00 0.17 ± 0.01 
20 0.15 ± 0.02 0.00 0.25 ± 0.04 0.25 ± 0.04 0.01 0.07 ± 0.01 0.00 0.16 ± 0.03 
21 <LOD 0.02 0.29 ± 0.03 0.29 ± 0.03 0.07 <LOD 0.02 <LOD 
22 0.07 ± 0.01 0.01 0.20 ± 0.01 0.18 ± 0.01 0.04 0.07 ± 0.01 0.04 0.28 ± 0.05 
23 <LOD 0.04 <LOD <LOD 0.24 0.14 ± 0.01 0.07 <LOD 
24 0.08 ± 0.01 0.01 <LOD <LOD 0.07 <LOD 0.02 <LOD 
25 0.58 ± 0.03 2.14 0.39 ± 0.02 0.41 ± 0.02 1.02 0.96 ± 0.02 3.10 0.41 ± 0.03 
26 <LOD 0.00 <LOD <LOD 0.04 <LOD 0.00 <LOD 
27 0.71 ± 0.04 1.83 0.66 ± 0.04 0.76 ± 0.04 0.86 <LOD 0.97 0.13 ± 0.01 
28 0.24 ± 0.02 1.02 0.50 ± 0.04 0.54 ± 0.04 0.79 0.79 ± 0.07 0.97 1.13 ± 0.09 
29 0.08 ± 0.01 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
30 0.22 ± 0.01 0.08 0.17 ± 0.01 0.15 ± 0.01 0.13 0.26 ± 0.02 0.06 0.13 ± 0.01 
31 <LOD 0.00 0.49 ± 0.02 0.52 ± 0.02 0.95 <LOD 0.00 <LOD 
32 <LOD 0.03 <LOD <LOD ND <LOD 0.03 <LOD 
33 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.00 <LOD 
34 1.17 ± 0.10 0.17 0.80 ± 0.07 0.96 ± 0.08 0.35 <LOD 0.10 <LOD 
35 <LOD 0.02 <LOD <LOD 0.04 <LOD 0.04 <LOD 
36 <LOD 0.02 <LOD <LOD 0.05 <LOD 0.04 <LOD 
37 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.00 <LOD 
38 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.00 <LOD 
 
39 <LOD 0.01 <LOD <LOD 0.03 <LOD 0.01 <LOD 
40 <LOD 0.01 0.53 ± 0.06 0.59 ± 0.07 0.10 <LOD 0.01 <LOD 
41 <LOD 0.01 0.07 ± 0.00 0.05 ± 0.00 0.03 <LOD 0.03 <LOD 
42 <LOD 0.00 0.07 ± 0.00 0.06 ± 0.00 0.15 <LOD 0.03 <LOD 
43 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
44 <LOD 0.12 1.38 ± 0.05 2.09 ± 0.08 0.29 0.14 ± 0.01 0.37 <LOD 
45 <LOD 0.03 <LOD <LOD 0.07 <LOD 0.15 <LOD 
46 <LOD 0.01 <LOD <LOD 0.03 <LOD 0.00 <LOD 
47 <LOD 0.04 <LOD <LOD 0.06 <LOD 0.09 0.07 ± 0.01 
48 <LOD 0.01 <LOD <LOD 0.01 <LOD 0.01 <LOD 
49 <LOD 0.02 <LOD <LOD 0.12 <LOD 0.11 <LOD 
50 <LOD 0.03 0.05 ± 0.01 0.05 ± 0.01 0.08 <LOD 0.03 <LOD 
51 <LOD 0.17 0.16 ± 0.04 0.15 ± 0.04 0.46 0.08 ± 0.02 0.30 <LOD 
52 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.00 <LOD 
53 <LOD 0.00 <LOD <LOD 0.04 0.36 ± 0.05 0.01 <LOD 
54 <LOD 0.00 <LOD <LOD 0.03 0.40 ± 0.01 0.00 <LOD 
55 <LOD 0.00 0.23 ± 0.03 0.23 ± 0.03 0.08 <LOD 0.03 <LOD 
56 <LOD 0.00 <LOD <LOD 0.03 <LOD 0.01 <LOD 
57 <LOD 0.00 <LOD <LOD 0.00 <LOD 0.00 <LOD 
58 <LOD 0.00 0.17 ± 0.01 0.16 ± 0.01 0.12 <LOD 0.01 <LOD 
59 <LOD 0.01 <LOD <LOD 0.05 <LOD 0.04 <LOD 
60 <LOD 0.00 <LOD <LOD 0.09 <LOD 0.00 <LOD 
61 <LOD 0.17 <LOD <LOD 0.33 0.14 ± 0.01 0.35 0.08 ± 0.01 
62 0.09 ± 0.01 0.03 0.16 ± 0.01 0.15 ± 0.01 0.24 <LOD 0.05 <LOD 
63 0.08 ± 0.01 0.43 0.18 ± 0.01 0.17 ± 0.01 0.99 <LOD 0.69 <LOD 
64 <LOD 0.00 <LOD <LOD 0.00 <LOD 0.00 <LOD 
65 0.91 ± 0.02 3.01 2.33 ± 0.08 7.27 ± 0.24 7.02 0.91 ± 0.03 3.76 1.21 ± 0.06 
66 <LOD 0.05 0.07 ± 0.00 0.06 ± 0.00 0.41 <LOD 0.03 <LOD 
67 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
68 <LOD 0.03 0.08 ± 0.02 0.07 ± 0.01 0.24 <LOD 0.21 0.13 ± 0.01 
69 <LOD 0.00 <LOD <LOD 0.02 <LOD 0.01 <LOD 
70 <LOD 0.01 <LOD <LOD 0.05 <LOD 0.25 <LOD 
71 <LOD 0.00 <LOD <LOD 0.01 <LOD 0.00 <LOD 
aHeterologous and bhomologous calibration; LOD: limit of detection 
 
CONCLUSION  
The optimization of a multiparametric luminescent detection 
immunoassay developed in this study makes possible to deter-
mine specific IgE below 0.1 IU/mL, which allows identifying 
allergic patients with higher sensitivity and specificity, using 
only 25 µL of serum. In addition, the use of ELISA plates al-
lows a multianalyte ELISA for screening antibiotic allergies. 
The use of a 96-well plate allows the analysis of specific IgE 
against four β-lactam antibiotics from 7 patients simultaneously 
and obtaining results in only one hour. In addition, CLIA is in-
expensive because it does not require high-cost equipment like 
other diagnostic methods and allows the test to be performed 
with the usual material that can be found in any laboratory. 
The developed CLIA has a clinical sensitivity of 64% and a 
specificity of 100%, making it a highly predictive assay for 
BLC antibiotic allergy. The detection limit set for CLIA is 
lower than the reference method. It might be thought that low-
ering the LOD would explain the increased clinical sensitivity, 
however there are studies that set assays with lower detection 
limit to those of ImmunoCAP but renders a decrease in clinical 
specificity3. A decrease in clinical specificity would result in an 
increase in the number of false positives, which would increase 
the number of people labelled as allergic to β-lactams when they 
are not. This incorrect labelling is an associated with negative 
clinical and administrative outcomes, including use of less de-
sirable alternative antibiotics, longer hospitalizations, increas-
ing antibiotic-resistant infections, and greater medical costs. 
CLIA makes it possible to increase clinical sensitivity while 
maintaining 100% clinical specificity, which translates into no 
false positives, contributing to "de-labeling", one of the main 
challenges in allergy diagnosis today. 
On the other hand, antibiotics are the main cause of immedi-
ate perioperative hypersensitivity (POH) reactions countries as 
 
Spain, the United States and the UK, where they represent 44%-
59% of IgE-mediated POH.23 The most frequently implicated 
antibiotics are β-lactams, especially amoxicillin because its 
widespread use. Due to the delicate state of the patients after an 
operation, the use of CLIA would allow a safe identification of 
those antibiotics that are causing the allergic reaction. 
In summary, we have developed a multiparametric immuno-
assay with luminescent detection that can be performed in any 
clinical laboratory and that allows the determination of specific 
IgE below 0.1 IU/mL with only 25 µl of serum and one hour of 
testing. Furthermore, thanks to its multiparametric perfor-
mance, it allows the screening of patients allergic to several an-
tibiotics, which provides valuable information when deciding 
which drug to treat the patient with and defining sensitization 
profiles. The clinical performance is good and represents a sig-
nificant improvement in the clinical sensitivity of the most cur-
rently used methods for the diagnosis of BLC antibiotic allergy. 
Consequently, CLIA allows the diagnosis of allergy to penicil-
lin G, penicillin V, amoxicillin and piperacillin with a high pre-
dictive value, in a cheap, fast and simple way. 
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